Implication for clinical practice

Combining interferon alfa-2a and -2b does not increase their effectiveness.

Table 26.4 Randomised controlled trials evaluating intralesional interferon in the treatment of basal cell carcinomas

Study

Method

Participants

Interventions

Outcomes

Notes

Alpsoy et al

Single centre

45 patients

T1: INF alfa-2a; T2:

FU: cytologic

Ex: Recurrent lesions,

199634 (Turkey)

Method of

HP BCC: T1: 15, T2:

INF alfa-2b; T3: INF

specimens taken

genetic or naevoid

randomisation

15, T3: 15 patients

alfa-2a and-2b

8 weeks after

conditions, deep

not known

Mean age T1: 587.

completion of

tissue involvement

ITT

T2: 63.6, T3:

therapy; all cases

60-3 years

evaluated clinically

Histological types

and histologically

T1:12 N, 1 S, 2 M; T2:

11 N, 2 S, 2 M; T3: 11

N, 2 S, 2 M

Cornell et al

Multicentre (4)

T1: 123, T2: 42

T1: intralesional

FU: weekly after each

Ex: Previously received

199035 (USA)

Randomisation

patients.

injections 1-5 million

of the three

therapy to test site,

by computer

BP BCC

IU IFN alfa-2b; T2:

treatments then at

immunosuppressive or

generated PP

Mean age T1: 56, T2:

vehicle for IFN

5, 9, 13 weeks after

cytotoxic therapy

57 years

preparation

completion of

(within previous

Histological type T1:

3 alternate days/week

treatment, then

4 weeks), or

57 S, 66 N ulcerative:

for 3 consecutive

every 3 months to

exogenous IFN/IFN

T2: 19 S, 23 N

weeks

52 weeks

alfa-2b (Intron A),

debilitating illness,

lesion in perioral or

central area of the

face or penetrating to

deep tissue

Edwards and

Single centre.

T1: 33; T2: 32

10 million IU zinc

BCC measured,

Ex: thromboembolic

Tucker 199036

Method of

patients

chelate IFN alfa-2b:

photographed before

disease, radiation

(USA)

randomisation

BP BCC

T1: single injection:

each treatment and at

therapy to the test site

not known PP

Age range 35-65

T2: one dose per

beginning of the 2nd,

area, history of arsenic

years

week for 3 weeks

8th, 12th and 16th

ingestion, pregnancy,

Histological type: T1:

week after the first

immunosuppression,

16 S, 17 N, T2: 15 S,

injection

receiving non-steroidal

15 N

Biopsy at week 16

anti-inflammatory

drugs, M BCC,

recurrent cancers,

deeply invasive

lesions, periorificial

tumours, central facial

BCC

Rogozlnski

Single centre.

T1: 17, T2: 18

T1: recombinant

FU: 16 weeks after

et al. 199737

Method of

patients

INF beta; T2: placebo

treatment and 2 years

(Poland)

randomisation

not known ITT

See Table 26.1 for abbreviations.

See Table 26.1 for abbreviations.

Dealing With Back Pain

Dealing With Back Pain

Deal With Your Pain, Lead A Wonderful Life An Live Like A 'Normal' Person. Before I really start telling you anything about me or finding out anything about you, I want you to know that I sympathize with you. Not only is it one of the most painful experiences to have backpain. Not only is it the number one excuse for employees not coming into work. But perhaps just as significantly, it is something that I suffered from for years.

Get My Free Ebook


Post a comment